Inovio Pharmaceuticals Inc. (NASDAQ:INO) at last check was buoying at $1.77 on Thursday, September 22, with a fall of -2.21% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $1.81 and 5Y monthly beta was reading 0.82 with its price kept floating in the range of $1.8009 and $1.95 on the day. Considering stock’s 52-week price range provides that INO hit a high price of $8.04 and saw its price falling to a low level of $1.38 during that period. Over a period of past 1-month, stock came subtracting -21.65% in its value.
With its current market valuation of $491.14 million, Inovio Pharmaceuticals Inc. is set to declare its quarterly results on Feb 28, 2022 – Mar 04, 2022. Analysts are in estimates of -$0.31 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.24 for 2022 with estimates of that growing to -$1.06 in next year. These estimates are suggesting current year growth of 14.50% for EPS and 14.50% growth next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $520k. The average estimate is representing an increase of 90.50% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $2.05 million in 2022, which will be 15.50% more from revenue generated by the company last year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review INO stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 100% Sell for it.
Digging deeper we become aware of the PEG ratio of the INO stock which is currently positioned at 0. It further provides that stock’s current price level is -17.84% away from its 20-day simple moving average and is -19.65% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 36.17 while volatility remained at 7.43% over the past week which changes to 7.55% when measuring it over the past month. Beta is valued at 0.83, while measure of average true range or ATR is currently at 0.16.
In comparing Inovio Pharmaceuticals Inc. (INO)’s stock with other industry players reveals that stock’s latest price change of -2.21% and that of -76.97% over the past 12 months is in competing position with that of Johnson & Johnson (JNJ) which saw its stock price raised by 1.74% in the recent trading and went through a decrease of -0.76% in past 12-month trading. Industry’s another major player Statera Biopharma Inc. (STAB) has fall -2.73% down in latest trading session, but over the past year has faced afall of -94.14% over the same period. Inovio Pharmaceuticals Inc. has a P/E ratio of 0 against that of Johnson & Johnson’s 23.74. On the other hand, the S&P 500 Index is down -0.73% in the early deals today while the Dow Jones Industrial was dealinglower at -0.29%.
Having a second look at Inovio Pharmaceuticals Inc. (NASDAQ:INO) provides that stock’s average daily trading volume for 3 months was 6.03 million, while it jumped to 6.15 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 249.40 million.
The percentage of outstanding shares held by the insiders is 0.50% while it is 46.30% for the institutional holders. The figures also indicate that as of Jul 14, 2022, number of stock’s short shares was 43.48 million which implies a short ratio of 6.4. This shows up a 18.98% of Short Interest in company’s outstanding shares on the day. In July the standing of shares short improved as it was 35.91 million in the previous month. Subtraction of -63.73% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.